Analysis of the bioactive molecules that enhance the induction and suppressive properties of human regulatory T cells and application to therapy
Project/Area Number |
21591282
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
膠原病・アレルギー・感染症内科学
|
Research Institution | Ehime University |
Principal Investigator |
HASEGAWA Hitoshi 愛媛大学, 大学院・医学系研究科, 准教授 (40164826)
|
Project Period (FY) |
2009 – 2011
|
Project Status |
Completed (Fiscal Year 2011)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | Regulatory T cells / Foxp3 / lipids / Peroxisome proliferator-activated receptor / 制御性T細胞 / PPAR / 核内受容体リガンド / lysophosphatidylcholine |
Research Abstract |
We screened 14 kinds of the molecules that enhanced the induction and suppressive function of human regulatory T cells(Treg) from lipid and nuclear receptor ligand libraries. Of these, PPAR agonists increased suppressive function and expression of Foxp3 in induced Tregs(iTregs). PPAR agonist-treated iTregs increased demethylation level of the Foxp3 promoter region and CNS3. Moreover, TSA and ATRA enhanced iTregs generation synergistically with PPAR agonists. On the other hand, lysophosphatidylcholine(LPC) enhances Foxp3 expression and the suppressive function of nTregs through TGF-beta1 produced by nTregs themselves. These agents increased Treg differentiation and induction and may be benefical for the treatment of human autoimmune diseases.
|
Report
(4 results)
Research Products
(25 results)